Free Trial
NASDAQ:IKNA

Ikena Oncology Q3 2024 Earnings Report

Ikena Oncology logo
$1.13 -0.08 (-6.61%)
Closing price 03:58 PM Eastern
Extended Trading
$1.12 0.00 (-0.44%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ikena Oncology EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Ikena Oncology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ikena Oncology Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Ikena Oncology's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Tuesday, May 13, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Ikena Oncology Earnings Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
William Blair Reaffirms Their Buy Rating on Ikena Oncology (IKNA)
See More Ikena Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ikena Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ikena Oncology and other key companies, straight to your email.

About Ikena Oncology

Ikena Oncology (NASDAQ:IKNA) operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

View Ikena Oncology Profile

More Earnings Resources from MarketBeat